Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAME (A*02) CAR-T
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PRAME (A*02) CAR-T is a discovery-stage chimeric antigen receptor (CAR) T-cell therapy being developed by Myrio Therapeutics for the treatment of neuroblastoma and other pediatric cancers. The therapy utilizes T cells engineered to express a CAR that specifically recognizes the PRAME (Preferentially Expressed Antigen in Melanoma) peptide when presented by the HLA-A*02 (Human Leukocyte Antigen A*02) complex. PRAME is a cancer-testis antigen that is highly expressed in various solid and hematologic malignancies but has limited expression in normal adult tissues, making it an attractive target for immunotherapy. By targeting the peptide-HLA complex, this approach allows the CAR-T cells to recognize intracellular tumor antigens that are typically inaccessible to conventional surface-targeting CARs, potentially expanding the range of treatable pediatric solid tumors.
- Other names
- PRAME CAR-TPRAME (A*02)
02
Targets
PRAME peptide–HLA complex
Beyond the preview
Go deeper on PRAME (A*02) CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME (A*02) CAR-T.